Posted by Michael Wonder on 14 May 2018
Decision to widen access and change the funded brand of tenofovir disoproxil and entecavir
14 May 2018 - PHARMAC is pleased to announce decisions to approve agreements with Teva Pharma New Zealand Limited and Novartis New Zealand Limited for the supply of tenofovir disoproxil and entecavir tablets, respectively, and to widen access to these treatments.
Tenofovir disoproxil and entecavir are antiviral medicines used for the treatment of hepatitis B and HIV.
These changes were the subject of a consultation letter dated 9 March 2018.
